Market Overview

Penny Stock Neovasc Rallies On Patent Abstract Filing

Share:
Penny Stock Neovasc Rallies On Patent Abstract Filing

Shares of the Canadian medical device maker Neovasc Inc (NASDAQ: NVCN) were rallying Tuesday following the circulation of a document with a patent abstract it filed with the U.S. Patent and Trademark Office.

The patent abstract pertains to the methods and apparatus for loading a prosthesis onto a delivery system. This relates to the company's Tiara prosthetic valve, which replaces the mitral valve of the heart when delivered through the apex of the heart.

"One or more actuators on the first housing may be actuated radially inward to selectively compress a discrete portion of the prosthesis disposed in the central bore," the document said.

A patent abstract is a short summary of the product and/or method for which a company is seeking to obtain a patent. The USPTO mandates that all non-provisional patent applications should be submitted with an abstract.

It is part of the patent application and is 150 words or less.

The USPTO can reject an abstract if it is not prepared in line with guidelines.The patent process is a lengthy one, and any interruption such as the rejection of an abstract will only serve to elongate the process. 

Neovasc shares were up 6.17 percent at 50 cents at the time of publication Tuesday. 

Related Links:

Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates

The Daily Biotech Pulse: Lilly Reports Positive Long-Term Efficacy Data For Psoriasis Drug, Provention Bio Offering

Posted-In: Biotech News Penny Stocks Markets Trading Ideas General Best of Benzinga

 

Related Articles (NVCN)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

'We're Trying To Be Smart About It': New Canopy Growth CFO Says Cannabis Company Eyeing Financing Options

American Express, Bank OF America, Occidental: 'Fast Money Halftime Report' Picks For June 11